Lv21
108 积分 2023-05-09 加入
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
2小时前
已完结
The Abundance of KRAS and RAS Gene Mutations in Cancer
25天前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
The KRAS crowd targets its next cancer mutations
2个月前
已完结
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
3个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
4个月前
已完结
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
5个月前
已完结
Antibody–drug conjugates for cancer
5个月前
已完结
Exploiting Synthetic Lethality in PDAC with Antibody Drug Conjugates and ATR inhibition
5个月前
已完结
皖公网安备34019202002308
